Journal of Oncology / 2009 / Article / Fig 2

Review Article

Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer

Figure 2

(a) Basic Structure of EGFR demonstrating relevant domains. (I) The extracellular domains: (1) domain I: L1; (2) domain II: CR1; domain III: L2; domain IV: CR2. (II) Transmembrane domains. (III) The intracellular domains (1) juxtamembrane domain; (2) tyrosine kinase domain; (3) regulatory region domain. The phosphorylation of several substrates by the tyrosine kinase domain of the EGFR receptor is responsible for activating the various signaling cascades seen in Figure 1. (b) Structure of domains I–IV of EGFR (no ligand bound). Note the “protruding loop” in domain II (CR1) directed away from the C-shaped region of the ligand-binding zone formed by domains I, II, and III. (c) The tyrosine kinase domain of EGFR showing the N-lobe and C-lobe flanking the activation loop and active site cleft [2, 3].

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.